These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10908846)

  • 1. Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium.
    Meluch AA; Burris HS; Greco FA; Hainsworth JD
    Eur J Cancer; 2000 Jul; 36 Suppl 2():30-3. PubMed ID: 10908846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
    Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
    J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
    Lorusso V; Crucitta E; Silvestris N; Rosati G; Manzione L; De Lena M; Palmeri S; Gebbia V; Mancarella S; Sobrero A; Pezzella G; Comella P; Mangiameli A; Muci D;
    Oncol Rep; 2005 Feb; 13(2):283-7. PubMed ID: 15643512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
    Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J;
    Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond.
    Cheng T
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):153-60. PubMed ID: 18685414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
    Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Albanell J; Tabernero JM; Cortés-Funes H; Baselga J
    Eur J Cancer; 2000 Jul; 36 Suppl 2():17-25. PubMed ID: 10908844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel in the management of advanced or metastatic urothelial tract cancer.
    Logothetis C; Millikan R
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):107-11. PubMed ID: 12108893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
    Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G;
    Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
    Lara PN; Meyers FJ; Law LY; Dawson NA; Houston J; Lauder I; Edelman MJ
    Cancer; 2004 Jan; 100(1):82-8. PubMed ID: 14692027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
    Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
    J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
    Li J; Juliar B; Yiannoutsos C; Ansari R; Fox E; Fisch MJ; Einhorn LH; Sweeney CJ
    J Clin Oncol; 2005 Feb; 23(6):1185-91. PubMed ID: 15718315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features.
    Shannon C; Crombie C; Brooks A; Lau H; Drummond M; Gurney H
    Ann Oncol; 2001 Jul; 12(7):947-52. PubMed ID: 11521800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed in transitional cell carcinoma of the urothelium.
    von der Maase H
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):48-50. PubMed ID: 15655937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.
    Demery ME; Thézenas S; Pouessel D; Culine S
    Anticancer Drugs; 2012 Feb; 23(2):143-8. PubMed ID: 21934599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
    Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
    J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
    Meluch AA; Greco FA; Burris HA; O'Rourke T; Ortega G; Steis RG; Morrissey LH; Johnson V; Hainsworth JD
    J Clin Oncol; 2001 Jun; 19(12):3018-24. PubMed ID: 11408496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine in transitional cell carcinoma of the urothelium.
    von der Maase H
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):11-9. PubMed ID: 12597345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium.
    Hoschke B; May M; Seehafer M; Helke C
    Int J Urol; 2004 Jul; 11(7):461-6. PubMed ID: 15242353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
    Gitlitz BJ; Baker C; Chapman Y; Allen HJ; Bosserman LD; Patel R; Sanchez JD; Shapiro RM; Figlin RA
    Cancer; 2003 Nov; 98(9):1863-9. PubMed ID: 14584068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
    Ecke TH; Gerullis H; Bartel P; Koch S; Ruttloff J
    Minerva Urol Nefrol; 2009 Mar; 61(1):1-8. PubMed ID: 19417721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.